Saluda Medical Pty Ltd

Saluda Medical Pty Ltd develops neuromodulation therapies for chronic pain. Its principal product, the Evoke System, is described as the world's first and only spinal cord stimulation (SCS) therapy controlled by evoked compound action potentials (ECAPs). The system objectively senses, measures and adjusts stimulation on every pulse, rather than delivering fixed output regardless of the spinal cord's response. Clinical data for the therapy extends out to 36 months.

The company's technical work spans closed-loop stimulation, ECAP sensing and measurement, real-time signal processing and diagnostics, and automated control algorithms. Its Dose-Control Technology applies these techniques to deliver personalised stimulation based on measured response. Saluda Medical reports more than 15 years of research and clinical experience, having sensed spinal cord responses since 2011, and holds what it describes as the world's largest database of ECAP measurements, running to trillions of readings.

Saluda Medical is headquartered in Australia, with offices in the United States and Europe, and operates globally. The company's evidence base includes more than 37 scientific publications and over 200 presentations at international conferences. Its stated focus is on redefining the standard of care in chronic pain management through clinical data and measured rather than assumed stimulation.